AstraZeneca (AZN) said Monday its investigational drug AZD0780 combined with standard-of-care statins reduced low-density lipoprotein, or LDL, cholesterol by 50.7% at 12 weeks in a phase 2b trial, with no need for fasting or food restrictions.
Among participants receiving AZD0780 30mg, 84% reached the recommended LDL-C target of under 70 mg/dL, compared with 13% on statins alone, the company said.
Elevated LDL-C is a known risk factor for serious cardiovascular conditions like heart attacks and strokes.
AZD0780 was generally well tolerated in the trial, with similar rates of adverse events and treatment discontinuation between the treatment and placebo groups, according to the company.
Price: 72.94, Change: -0.86, Percent Change: -1.16
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。